Bernd Schollmeier

• Strategic Asset Strategy & Portfolio De-risking: Provide board-level commercial counsel across vaccines, monoclonal antibodies, oncology, and rare diseases, maintaining full P&L ownership and managing an elite international expert network to support academic spin-offs, research organisations, and global biopharma clients.

• Managed Entry Agreement Architecture: Developed a proprietary, interconnected value framework detailing precise execution pathways across European HTA alignment (EU4 focus), floor pricing architecture, innovative sick-fund contracting, and government advocacy to successfully insulate pipeline asset valuations.

• Strategic Market Access Training for Vaccines: Exclusively conceptualised and executed a bespoke commercialisation and market access curriculum in 2025 for a German federal governmental body, establishing independent commercial architecture, public procurement strategies, and national batch-testing frameworks for young researchers, clinical innovators, and university spin-offs.

• Early-Stage Pipeline Valuation: Conducted multi-layered asset valuations, Net Present Value (NPV) analyses, and Target Product Profile (TPP) optimisations for advanced biological and vaccine assets, directly accelerating financing readiness and international market entry.

• High-Stakes Client Advisory: Retained as an elite external partner to provide board-level strategic counsel to multinational pharmaceutical clients, directing international market access and pricing frameworks for advanced biologicals, vaccines, and orphan drugs.

• Combination Vaccine Market Entry: Spearheaded the global access and pricing architecture for a breakthrough combination vaccine targeting Respiratory Syncytial Virus (RSV) and human Metapneumovirus (hMPV) for a top-tier global pharmaceutical leader.

• Strategic Market Analysis & Indication Pivot: Executed a comprehensive market analysis for a Hepatitis B (HepB) antibody project with the University of Lübeck; strategically pivoted the asset's clinical indication from a low-probability therapeutic approach to a preventive monoclonal antibody, successfully increasing forecasted peak sales from USD 50M to USD 500M.

• Pan-European Payer & Advisory Governance: Frameworked and moderated a highly specialized European RSV Advisory Board, gathering key public health stakeholders, national immunisation technical advisory groups (NITAGs), and payers to align regional funding pathways.

• Cross-Border Value Stabilization: Advised global product teams on floor price governance, international reference pricing (IRP) mitigation, and launch sequencing across complex European and intercontinental market archetypes.

• Executive Training & Advisory Boards: Launched a global market access training programme for vaccines. Conceptualised elite payer advisory boards, EU/UK stakeholder strategies, and specialised government negotiation frameworks.

• Global Thought Leadership ("VacciTalks"): Hosted the "VacciTalks" podcast, interviewing global vaccine leaders (e.g. former Chair of STIKO Prof. Dr. Joe Schmitt). Covered the Registration vs. Recommendation Chasm, CMC bottlenecks, saRNA platforms, and the 100-Day Benchmark across WHO SAGE, PEI, and NITAGs.

• Rare Disease & Haematology Market Entry: Developed comprehensive commercial business cases, pricing architecture, and European market entry frameworks for international biotechnology clients launching specialised orphan drugs and high-cost haematology therapies.

• Asset Valuation & Pipeline Optimisation: Conducted multi-layered asset valuations, Net Present Value (NPV) analyses, and target product profile (TPP) optimisations for early-stage biological pipelines, enabling biotechs to secure venture funding and strategic partnerships.

• Cross-Border Reference Pricing Architecture: Designed proactive risk-mitigation strategies and global floor price governance frameworks to insulate premium therapeutic assets from European International Reference Pricing (IRP) erosion.

• Value Proposition Refinement: Partnered with executive leadership teams at emerging biotech start-ups to translate early clinical and real-world evidence (RWE) into compelling value propositions tailored to the requirements of European Health Technology Assessment (HTA) bodies.

• Single-Dose Hepatitis Strategy: Formulated the strategic launch architecture and market access frameworks for a novel single-dose Hepatitis vaccine pipeline, specifically mapping commercialisation pathways across Germany and the UK.

• Global Influenza Advisory: Provided high-level strategic commercial input and market insights to refine the long-range global influenza vaccine strategy for a major multinational pharmaceutical producer.

• Transcontinental Vaccine Market Assessment: Maintained a dedicated advisory workstream supporting several prominent Asian vaccine manufacturers evaluating market entry into Europe and Canada. Evaluated regional pricing dynamics, reimbursement mechanisms, and the highly critical clinical evidence requirements needed to clear National Immunisation Technical Advisory Group (NITAG) recommendation thresholds.